학술논문
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
Document Type
Article
Author
Source
In Annals of Oncology April 2020 31(4):507-516
Subject
Language
ISSN
0923-7534